Table 4.

Odds ratios for adverse pregnancy outcome (n=40) among 149 pregnancies

Predictor	Number of occurrences	Univariable OR (95% CI)	Model 1* OR (95% CI)	Model 2# OR (95% CI)
Organ-specific activity six months prior to conception
Cytopenia	17	2.6 (0.8–8.5)	1.8 (0.5–6.0)	1.6 (0.5–5.4)
Nephritis	10	7.3 (1.5–35.2)	4.6 (0.9–23.4)	3.3 (0.6–17.9)
Skin disease	15	1.0 (0.3–3.9)	1.3 (0.4–5.0)	1.2 (0.3–4.8)
Arthritis	13	0.8 (0.2–3.6)	0.7 (0.1–3.2)	0.7 (0.1–3.0)
Serositis	5	1.8 (0.2–14.1)	1.6 (0.2–12.7)	1.0 (0.1–7.8)
Organ-specific activity during pregnancy
Cytopenia	23	4.8 (1.7–14.0)	4.2 (1.4–12.2)	3.9 (1.3–11.4)
Nephritis	16	4.4 (1.3–14.9)	3.5 (1.0–12.2)**	3.6 (1.0–12.8)$
Skin disease	13	1.9 (0.5–7.1)	1.3 (0.3–5.4)	1.3 (0.3–5.2)
Arthritis	8	3.2 (0.6–16.2)	3.7 (0.8–18.5)	3.9 (0.8–19.7)
Serositis	8	4.8 (0.9–25.5)	5.7 (1.1–30.3)	5.9 (1.0–34.0)++

Adverse pregnancy outcome: pre-eclampsia, preterm <37 weeks, miscarriage (fetal loss at 12–20 weeks gestation), stillbirth (fetal loss at ≥20 weeks gestation), SLE-related elective termination

OR and 95% CI from generalized linear mixed models to account for correlated data among 114 women carrying a total of 149 pregnancies

^*Model 1: adjusted for ethnicity (Hispanic/non-Hispanic) and prior adverse pregnancy outcome

^#Model 2: model 1 + corticosteroid and/or azathioprine use six months before conception, and hydroxychloroquine use six months before conception

^**p=0.046

^$p=0.045

⁺⁺p=0.049